Our first pick today just received an upgrade from Morgan Stanley, to ‘Overweight’ and our second recommendation is a short sale.
Buy: Myriad Genetics (MYGN)
From Shortex Market Letter
52wk H. $44.40 52wk L. 23.28
Mkt Cap: $3.07BB, EPS: 1.94, P/E: 27.72 Beta: 1.02
Myriad Genetics (MYGN) is a molecular diagnostic Co. focusing on novel predictive/personalized medicine. Coverage decision by Kroger ® prescription plans for Vectra DA ® enhances Co’s ability to improve the cost of care for patients with rheumatoid arthritis. Death cross pattern being reversed since 05/08/18 to golden cross pattern: gapped-up (28-34) to (34-38) to (39-42) to new high of 44.40.
BUYING RANGE: 38-44
NR TERM OBJ: 57
INTERMED OBJ: 69
STOP LOSS: 32
Joseph Parnes, Shortex Market Letter, www.shortex.com, 800-877-6555, July 27, 2018